NLE Gastrointestinal Nursing — Hepatic, Biliary & Pancreatic DisordersStudy Notes

Viral hepatitis is inflammation of the liver caused by five distinct viruses (A through E), each with unique transmission routes, chronicity, and public-health implications. The fundamental distinction for NLE purposes is the **transmission route: Hepatitis A and E are transmitted via the fecal-oral route** (contaminated food and water, often remembered as 'Enter' from the enteritis-like transmission), while **Hepatitis B, C, and D are transmitted via blood and body fluids.** This distinction guides infection-control precautions and prevention strategies. **HEPATITIS A (HAV):** - **Transmission:** Fecal-oral (contaminated food, water, poor sanitation). - **Chronicity:** Acute only—does NOT progress to chronic infection. - **Clinical course:** Self-limiting; most patients recover completely within weeks to months. - **Vaccine:** Yes, highly effective (inactivated HAV vaccine). - **Prevention focus:** Handwashing, sanitation, food safety, vaccination. - **Public-health context:** Common in areas with poor sanitation; endemic in the Philippines among certain populations. **HEPATITIS B (HBV):** - **Transmission:** Blood, body fluids, sexual contact, and perinatal (mother-to-child). - **Chronicity:** YES—5-10% of infected adults develop chronic infection; 90% of infected infants progress to chronic HBV. - **Vaccine:** Yes, and highly effective (3-dose series or 4-dose series if combined); **newborns of HBsAg-positive mothers must receive hepatitis B immunoglobulin (HBIG) and vaccine within 12 hours of birth.** - **Key serologic markers:** - **HBsAg (hepatitis B surface antigen):** indicates active infection or carrier state. - **Anti-HBs (anti-hepatitis B surface antibody):** indicates immunity from vaccination or recovery. - **Anti-HBc IgM:** indicates acute infection. - **HBeAg (hepatitis B e antigen):** indicates high infectivity. - **Complication risk:** Chronic HBV leads to cirrhosis, hepatocellular carcinoma (HCC), and liver failure—major drivers of liver disease mortality in the Philippines. - **Public-health context:** **Highly endemic in the Philippines;** universal infant HBV vaccination (birth dose within 24 hours) is a cornerstone of the National Immunization Program. Antenatal HBsAg screening, blood-supply screening, and safe injection practices are critical. Many chronically infected adults are asymptomatic carriers, necessitating screening and vaccination of household and sexual contacts. **HEPATITIS C (HCV):** - **Transmission:** Blood primarily (intravenous drug use, blood transfusion prior to 1992, needlestick injury). - **Chronicity:** YES—75-85% of infected persons develop chronic HCV, making it the **most common cause of chronic viral hepatitis globally.** - **Vaccine:** No vaccine available. - **Treatment revolution:** Direct-acting antivirals (DAAs) now achieve cure rates >95% with 8-12 weeks of therapy; genotype 1 (historically most difficult to treat) is now curable. - **Key marker:** Anti-HCV antibody (indicates current or past infection; requires confirmatory viral load/HCV RNA for active infection diagnosis). - **Prevention:** Blood supply screening, safe injection practices, counseling of PWID (persons who inject drugs). **HEPATITIS D (HDV—Delta Hepatitis):** - **Transmission:** Blood and body fluids—**but ONLY in the presence of HBV** (it is a defective virus that requires HBV surface antigen to replicate). - **Chronicity:** YES—when present with HBV, HDV causes more severe liver disease and accelerates progression to cirrhosis. - **Prevention:** HDV is automatically prevented by HBV vaccination, since it cannot exist without HBV. - **Diagnostic marker:** Anti-HDV antibody and HDV RNA. **HEPATITIS E (HEV):** - **Transmission:** Fecal-oral (contaminated water; rare in developed countries, endemic in developing regions). - **Chronicity:** Usually acute; however, immunocompromised persons may develop chronic HEV. - **Special danger:** **HEV in pregnancy carries a SIGNIFICANTLY higher mortality rate (15-25%) compared to non-pregnant individuals (0.5-4%);** this is a classic NLE pearl. - **Prevention:** Water safety, sanitation; no vaccine in most countries (vaccines developed but not widely available). **HEPATITIS COMPARISON TABLE—QUICK REFERENCE:** | Feature | HAV | HBV | HCV | HDV | HEV | |---------|-----|-----|-----|-----|-----| | **Transmission** | Fecal-oral | Blood/fluids, sexual, perinatal | Blood | Blood (with HBV only) | Fecal-oral | | **Chronic?** | No | Yes (5-10% adults, 90% infants) | Yes (75-85%) | Yes (with HBV) | Usually no | | **Vaccine** | Yes | Yes | No | No (prevent HBV) | No (few countries) | | **Danger in pregnancy** | Low | Moderate | Low | Moderate | **HIGH (15-25% mortality)** | | **Most common chronic** | N/A | Yes, historically | Yes, now (especially G1) | N/A | N/A | **CLINICAL PHASES OF ACUTE VIRAL HEPATITIS (ALL TYPES):** 1. **Prodromal (Pre-icteric) Phase (days 1-7):** Anorexia, nausea, vomiting, malaise, fatigue, low-grade fever, right-upper-quadrant (RUQ) discomfort, sometimes myalgias and arthralgia. Liver enzymes (ALT, AST) begin to rise; no jaundice yet. Patient is often most infectious during this phase. 2. **Icteric Phase (days 7-21):** **Jaundice** (yellowing of skin and sclera from elevated bilirubin), **dark/tea-colored urine (bilirubinuria)**, **pale/clay-colored stools** (reduced bile flow), and **pruritus (itching).** RUQ tenderness and hepatomegaly may be present. ALT/AST peak and begin to decline; bilirubin peaks mid-phase. Jaundice is most visible this week. 3. **Convalescent Phase (weeks 3-6 or longer):** Jaundice and other symptoms resolve, though **fatigue may linger for weeks to months.** Appetite returns. Liver enzymes normalize. **DIAGNOSTIC MARKERS IN ACUTE VIRAL HEPATITIS:** - **Serum aminotransferases (ALT and AST):** Both markedly elevated; **ALT is more liver-specific** (AST is also found in muscle and heart). In acute viral hepatitis, **ALT often exceeds AST** (opposite of alcoholic hepatitis where AST > ALT). - **Elevated total and conjugated (direct) bilirubin:** Causes the jaundice and dark urine. - **Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT):** Mildly elevated or normal in acute viral hepatitis; markedly elevated if biliary obstruction is present. - **Serologic testing:** Specific antibodies and antigens identify the viral type (HBsAg, anti-HBc IgM, anti-HCV, anti-HAV IgM, etc.). - **Prothrombin time (PT) and INR:** Usually normal unless severe hepatitis; if prolonged, signals fulminant failure. **NURSING MANAGEMENT OF ACUTE VIRAL HEPATITIS:** - **Rest:** Activity as tolerated; fatigue dictates activity level. - **Nutrition:** Small, frequent, high-calorie meals (6-8 per day) to prevent catabolism. Diet is typically **high carbohydrate, moderate protein, low fat** to ease digestion and reduce nausea. Adequate hydration (8-10 glasses water/day unless contraindicated). - **Medications to AVOID:** Alcohol (absolute contraindication—hepatotoxic and delays recovery), acetaminophen/paracetamol (hepatotoxic, especially in liver disease), sedatives (increase infection risk), and any unnecessary hepatotoxic drugs. - **Infection control:** - **For HAV and HEV (fecal-oral transmission):** Contact precautions in addition to standard precautions; hand hygiene after toileting is critical; separate bathroom or meticulous cleaning after use; soiled items isolated. - **For HBV, HCV, HDV (blood/body fluids):** Standard precautions; blood/body fluid precautions; safe handling of all potentially contaminated materials. - **Vaccination:** **Hepatitis B vaccine (3-dose series) for susceptible contacts of HBsAg-positive patients;** **post-exposure prophylaxis with HBIG** for needlestick injuries or sexual exposure to HBV-positive persons. - **Immunoglobulin (Ig) for HAV:** Passive immunization (anti-HAV) for **close contacts within 2 weeks of exposure** (before seroconversion). - **Newborns of HBsAg-positive mothers:** **HBIG 0.5 mL IM and first dose of HBV vaccine within 12 hours of birth;** this is a critical Philippine public-health intervention to prevent vertical transmission and chronic HBV in infants. - **Monitoring:** Serial ALT/AST, bilirubin, PT/INR; observe for signs of fulminant failure (encephalopathy, coagulopathy, hypoglycemia). **HIGH-YIELD NLE POINTS ON VIRAL HEPATITIS:** 1. **A & E = Fecal-oral ("Enter" end); B, C, D = Blood/body fluids.** 2. **Hepatitis B is endemic in the Philippines—vaccine + HBIG for newborns of HBsAg+ mothers within 12 hours of birth.** 3. **HDV exists ONLY with HBV; prevented by HBV vaccine.** 4. **HEV in pregnancy is DANGEROUS (15-25% mortality).** 5. **HCV is the most common chronic viral hepatitis and now curable with DAAs.** 6. **ALT > AST in acute viral hepatitis (opposite in alcoholic hepatitis).** 7. **Avoid alcohol, acetaminophen, and sedatives in all liver disease.**

**Cirrhosis** is the endpoint of chronic liver injury, characterized by irreversible **hepatic fibrosis and nodular regeneration** replacing normal liver parenchyma. It is a leading cause of morbidity and mortality in the Philippines, driven by chronic hepatitis B, hepatitis C (historically), alcohol-related liver disease, and increasingly, non-alcoholic fatty liver disease (NAFLD). **PATHOPHYSIOLOGY:** Chronic hepatic inflammation (from viral hepatitis, alcohol, toxins, or autoimmune disease) triggers **hepatic stellate cell activation**, which produces excessive collagen and fibrous tissue. Over time, normal hepatocyte architecture is replaced by fibrous septa and regenerative nodules. This process is **largely irreversible**—while some antiviral or abstinence interventions may slow progression, established cirrhosis cannot be reversed by medical therapy alone (transplantation is curative). The loss of hepatocyte mass and architectural distortion lead to: 1. **Impaired hepatic synthetic function:** ↓ albumin, ↓ clotting factors (PT/INR prolonged), ↓ detoxification of ammonia, bilirubin, and drugs. 2. **Portal hypertension:** Increased resistance to blood flow through the fibrotic liver raises portal pressure, driving ascites, variceal bleeding, and splenomegaly. **CLINICAL MANIFESTATIONS OF CIRRHOSIS:** **Early/Compensated Cirrhosis:** - Fatigue, anorexia, weight loss, nausea, mild RUQ discomfort. - Hepatomegaly (firm, nodular edge) or a small hard liver (late). - Labs may show mild elevations in aminotransferases and bilirubin; PT/INR may be normal. **Advanced/Decompensated Cirrhosis:** - **Jaundice** (from impaired bilirubin conjugation/excretion). - **Ascites** (fluid in the peritoneum) causing abdominal distension, weight gain, and respiratory compromise. - **Peripheral edema** (ankles, sacrum) from hypoalbuminemia and sodium retention. - **Spider angiomata** (telangiectasias with central arteriole and radiating legs, blanch with pressure) on trunk—sign of portal hypertension. - **Palmar erythema** (reddening of palms, especially thenar/hypothenar eminences) from altered estrogen metabolism. - **Gynecomastia** (breast enlargement in males) from relative estrogen excess and androgen deficiency. - **Easy bruising and bleeding** (petechiae, ecchymoses, spontaneous epistaxis, gum bleeding) from ↓ clotting factors and thrombocytopenia. - **Hepatic encephalopathy** (see separate section below): confusion, asterixis, fetor hepaticus, progressing to coma. - **Fetor hepaticus** (musty, fruity breath odor) from accumulated methyl mercaptan and other volatile toxins. **LABORATORY FINDINGS IN CIRRHOSIS:** - **Aminotransferases (ALT/AST):** Often only mildly elevated or normal (reflecting hepatocyte loss rather than active inflammation). - **Alkaline phosphatase:** Mildly to moderately elevated. - **Bilirubin:** Elevated (mostly conjugated), worsens with decompensation. - **Albumin:** LOW (usually <3.5 g/dL)—reflects impaired synthesis and is a poor prognostic sign. - **Prothrombin time (PT) and INR:** **PROLONGED**—critical indicator of synthetic dysfunction; does NOT normalize with vitamin K in cirrhosis (unlike biliary obstruction). - **Ammonia:** Elevated (correlates with encephalopathy risk). - **Platelets:** LOW (thrombocytopenia from bone marrow suppression and splenic sequestration in portal hypertension). - **Sodium:** Often LOW (hyponatremia from SIADH, renal dysfunction, and fluid retention). - **Creatinine and BUN:** May be elevated (hepatorenal syndrome) or low (poor nutritional status, impaired synthesis of urea-cycle enzymes). **Child-Pugh Score (for Cirrhosis Severity and Prognosis):** Classifies cirrhosis into Classes A (mild), B (moderate), and C (severe) based on bilirubin, albumin, PT/INR, presence of ascites, and encephalopathy. Class C has the poorest prognosis and is an indication for liver transplant evaluation. NLE questions may reference this staging. **MAJOR COMPLICATIONS OF CIRRHOSIS (FROM PORTAL HYPERTENSION & HEPATIC DYSFUNCTION):** **1. ASCITES (Peritoneal Fluid Accumulation)** **Mechanism:** Portal hypertension ↑ hydrostatic pressure in splanchnic vasculature → fluid weeping into peritoneal cavity. Additionally, hypoalbuminemia (↓ plasma oncotic pressure) and secondary hyperaldosteronism (Na+ and water retention) worsen ascites. Splanchnic vasodilation and renal vasoconstriction (from nitric oxide dysregulation) further exacerbate the process. **Clinical signs:** - Abdominal distension, weight gain (sudden, often 2-3 kg over days). - Shifting dullness (percussion) and fluid wave (palpation) on exam. - Dyspnea (from diaphragmatic compression) and orthopnea. - Umbilical hernia protrusion (from increased intra-abdominal pressure). **Nursing assessment & management:** - **Daily weight:** Essential; gain >2 kg/day suggests fluid retention; loss >0.5-1 kg/day suggests adequate diuresis (should not exceed 1 kg/day to avoid azotemia). - **Abdominal girth measurement:** Serial measurements (mark level at umbilicus) help quantify ascites. - **Strict sodium restriction:** 500-1000 mg/day (very restrictive); patient must avoid salt, processed foods, cured meats, cheese, canned soups. Patient education is challenging; involve dietitian. - **Fluid restriction:** Usually 1-1.5 L/day if hyponatremia (Na+ <130 mEq/L) is present. - **Diuretics:** **Spironolactone 100 mg/day** (potassium-sparing aldosterone antagonist) is first-line; increase to 400 mg/day in divided doses as tolerated. **Furosemide 40-80 mg/day** is added if spironolactone alone is inadequate. **Maintain a spironolactone-to-furosemide ratio of 100:40** to minimize electrolyte imbalance. Monitor for hyperkalemia (spironolactone) and hypokalemia (furosemide), hyponatremia, and azotemia (rising creatinine). - **Monitoring labs:** Serum electrolytes (K+, Na+, Cl-), creatinine, BUN every 3-7 days during diuretic initiation; monthly once stable. - **Paracentesis:** Indicated for **tension ascites** (causing respiratory distress, abdominal pain, or risk of umbilical hernia rupture), diagnostic purposes (suspect spontaneous bacterial peritonitis [SBP]), or therapeutic relief if refractory to medical management. **Post-paracentesis monitoring:** Vital signs, abdominal exam for peritonitis signs, careful observation for hypotension (albumin infusion 6-8 g per liter of fluid removed may prevent post-paracentesis circulatory dysfunction in large-volume paracentesis). **Ascites-related complications:** - **Spontaneous bacterial peritonitis (SBP):** Infection of ascitic fluid without an identifiable source; presents with fever, abdominal pain, encephalopathy, or worsening clinical status. Diagnosis: ascitic fluid PMN >250 cells/μL (absolute PMN count, not total WBC). Treatment: antibiotics (cefotaxime 2 g IV q4-6h or similar 3rd-generation cephalosporin) and albumin. Prevention: **norfloxacin 400 mg daily** in patients with ascites and low ascitic fluid protein (<1.5 g/dL) or with prior SBP. - **Hepatorenal syndrome (HRS):** Progressive renal failure (rising creatinine) in the setting of liver disease and ascites, from severe splanchnic and renal vasoconstriction. Ominous sign; mortality is high without transplant. Treatment: vasoconstrictors (terlipressin) and albumin, renal replacement therapy if needed. **2. ESOPHAGEAL VARICES (Portal Hypertension-Driven Variceal Bleeding)** See detailed section below (Section 3). **3. HEPATIC ENCEPHALOPATHY (Hepatic Encephalopathy)** See detailed section below (Section 4). **4. SPONTANEOUS BACTERIAL PERITONITIS (SBP)** Discussed above under ascites complications. **5. COAGULOPATHY & BLEEDING RISK** - **Impaired synthesis of clotting factors** (II, V, VII, IX, X, XII)—PT/INR reflects this. - **Thrombocytopenia** from bone marrow suppression and splenic pooling. - **Esophageal/gastric variceal bleeding** (life-threatening). - **Portal hypertensive gastropathy** (mucosal bleeding). - **Nursing bleeding precautions:** Soft toothbrush or foam stick (NOT hard-bristle), electric razor (NOT blade), avoid IM injections (risk of hematoma), NO aspirin or NSAIDs (inhibit platelets, increase GI bleed risk), careful BP monitoring (tight cuff use can cause bruising), gentle handling, monitor stools/vomitus for blood. **NURSING DIAGNOSES & PRIORITIES IN CIRRHOSIS (Using NANDA and Maslow):** **Safety/Physiologic (Life Threat):** - **Risk for Bleeding** related to impaired clotting factor synthesis, thrombocytopenia, and portal hypertension → Implement bleeding precautions; monitor Hgb/Hct and coagulation studies; educate on signs of bleeding. - **Risk for Aspiration** related to hepatic encephalopathy and impaired gag reflex → Position semi-Fowler's or higher; monitor mental status; NPO if encephalopathy worsening. - **Risk for Acute Confusion** (Hepatic Encephalopathy) related to elevated ammonia and impaired hepatic detoxification → Monitor orientation, asterixis; administer lactulose/rifaximin; assess for precipitating factors. **Fluid & Electrolyte:** - **Excess Fluid Volume** (Ascites) related to portal hypertension, hypoalbuminemia, and sodium retention → Sodium restriction, diuretics, daily weight, girth, strict I&O. - **Risk for Electrolyte Imbalance** (Hypokalemia, Hyponatremia) related to diuretics and liver dysfunction → Monitor labs, replace electrolytes, teach about dietary sources. **Nutrition:** - **Imbalanced Nutrition: Less Than Body Requirements** related to anorexia, nausea, early satiety from ascites, and protein malnutrition → Small frequent meals, nutritional supplements, address nausea, involve dietitian. **Skin Integrity:** - **Impaired Skin Integrity** related to jaundice-induced pruritus, edema, and ascites → Keep skin cool and dry, short nails, cool compresses, avoid harsh soaps, monitor for breakdown over bony prominences. **NURSING CARE SUMMARY FOR CIRRHOSIS:** - **Monitor:** Neuro status (asterixis, orientation) q shift; vital signs; daily weight and abdominal girth; I&O; stools (color, consistency, blood); vital signs post-paracentesis. - **Restrict:** Sodium (500-1000 mg/day), fluid (if hyponatremia), and protein (cautiously, only in acute encephalopathy; prolonged restriction causes malnutrition). - **Administer:** Spironolactone ± furosemide, lactulose, rifaximin, PPI (omeprazole, famotidine), vitamin supplements (thiamine, folate, vitamin A, K), and albumin if paracentesis or HRS. - **Teach:** Sodium-restricted diet (work with dietitian), adherence to medications, signs of bleeding and encephalopathy, avoid alcohol absolutely, need for regular follow-up and possible transplant evaluation. - **Psychosocial:** Cirrhosis is life-limiting; address fears, depression, family dynamics, and substance-abuse counseling if alcohol-related.

**Hepatic encephalopathy (HE)** is a neuropsychiatric complication of advanced liver disease (cirrhosis, acute fulminant hepatitis, or portal vein thrombosis with large portosystemic shunts) resulting from accumulation of **ammonia and other neurotoxic substances** that the failing liver cannot detoxify. It ranges from subtle cognitive changes to coma and is a medical emergency in severe forms. **PATHOPHYSIOLOGY:** Under normal conditions, ammonia (NH3) produced by gut bacteria and amino acid metabolism is transported to the liver via the portal vein, where the **urea cycle** (primarily in periportal hepatocytes) converts ammonia to urea for renal excretion. In cirrhosis: 1. **Hepatocyte loss and dysfunction** impair ammonia metabolism. 2. **Portal hypertension** creates **portosystemic shunts** (varices, internal vein collaterals) that allow ammonia and other metabolites to **bypass the liver and enter systemic circulation** → **hyperammonemia**. 3. **Ammonia (NH3) diffuses across the blood-brain barrier,** enters astrocytes, and is converted to **glutamine** (via glutamine synthase), depleting glutamate (a neurotransmitter) and disrupting neural signaling. Ammonia also impairs K-Cl co-transport, causing astrocyte swelling and cerebral edema. 4. **Other neurotoxins** (manganese, false neurotransmitters like octopamine, endogenous benzodiazepines) compound the encephalopathy. 5. **Systemic inflammatory mediators** and **oxidative stress** further compromise neuronal function. **CLINICAL MANIFESTATIONS (West Haven Grading):** **Grade 1 (Minimal):** Subtle cognitive changes—poor concentration, mild memory loss, slow thinking, mood changes (depression, irritability); **asterixis (flapping tremor)** may be detected on exam. **Grade 2 (Mild):** Lethargy, confusion, disorientation to time and place, inappropriate behavior, asterixis. **Grade 3 (Moderate):** Somnolence, further disorientation, sometimes combative; asterixis and **fetor hepaticus** (fruity, musty breath). **Grade 4 (Severe):** **Coma** — unrousable; loss of protective airway reflexes (aspiration risk); signs of cerebral edema (Cushing's triad: hypertension, bradycardia, irregular respirations). **Key clinical signs:** - **Asterixis (flapping tremor):** Ask patient to extend arms, wrists cocked back; observe for rapid downward jerks and return. Classic sign of encephalopathy but NOT specific (also seen in uremia, hypercapnia, hypoglycemia, and sedative toxicity). - **Fetor hepaticus:** Characteristic musty, slightly fruity odor of the breath—from methyl mercaptan and dimethyl sulfide (volatile metabolites the liver cannot detoxify). - **Impaired mentation:** Confusion, disorientation, poor recall, slowed responses. - **Altered sleep-wake cycle:** Daytime somnolence, nighttime agitation. **PRECIPITATING FACTORS (Critical to Identify & Correct):** 1. **Increased ammonia production:** - **Gastrointestinal bleeding** (protein meals for bacteria → more ammonia; blood = protein load). - **High protein intake** (especially if liver disease counseling not done). - **Constipation or decreased GI motility** (ammonia reabsorption from colon). - **Infection** (UTI, pneumonia, SBP, other)—increases protein catabolism and ammonia generation. - **Renal failure** (impaired ammonia excretion). 2. **Impaired ammonia metabolism:** - **Medications:** Sedatives, opioids, diuretics (cause alkalosis, favoring NH3 over NH4+), benzodiazepines. - **Hypokalemia** (alkalosis favors NH3 over NH4+ formation). - **Liver disease progression.** 3. **Other triggers:** - **Hypoalbuminemia** (reduced ammonia binding). - **TIPS (transjugular intrahepatic portosystemic shunt)** placement (increased shunting of ammonia). - **Hepatocellular carcinoma** (disease progression). **DIAGNOSTIC APPROACH:** - **Serum ammonia:** Elevated (>40 μmol/L); however, **ammonia level does NOT perfectly correlate with clinical severity**, and a normal ammonia does not rule out HE. Ammonia is useful for trend monitoring. - **Arterial or venous blood gas:** Assess pH (alkalosis worsens HE), pCO2 (hypercapnia can worsen), and oxygenation. - **Electrolytes:** Hypokalemia, hyponatremia, azotemia. - **Blood glucose:** Hypoglycemia can worsen confusion. - **Liver function tests:** Reflect underlying liver disease severity. - **Blood and urine cultures, urinalysis:** Screen for infection (common precipitant). - **CT or MRI head:** To rule out subdural hematoma, stroke, or other intracranial pathology (especially if first HE episode or atypical presentation). - **EEG:** May show slowing; not routinely done for diagnosis. **MANAGEMENT OF HEPATIC ENCEPHALOPATHY:** **1. IDENTIFY & CORRECT PRECIPITATING FACTORS:** - **Bleeding:** IV access, blood products, octreotide infusion, endoscopy (varices). - **Infection:** Broad-spectrum antibiotics (cover gram-negatives, gram-positives). - **Constipation:** Lactulose, osmotic laxative, enema if needed. - **Hypokalemia:** IV or PO potassium replacement. - **Medications:** Discontinue sedatives, opioids, diuretics if possible; minimize CNS-active drugs. **2. AMMONIA REDUCTION VIA LACTULOSE (Gold Standard):** **Mechanism of action:** - **Lactulose** is a **non-absorbable disaccharide** (galactose + fructose linked by β-1,4 bond). - **In the colon,** lactulose is **fermented by colonic bacteria** into **lactate and acetate,** which **lower colonic pH (acidify the colon).** - **Ammonia in equilibrium:** NH4+ (ammonium, ionized, water-soluble) ↔ NH3 (ammonia, unionized, lipid-soluble). - **At neutral/basic pH:** NH3 (uncharged) is favored; it is lipid-soluble and **crosses cell membranes and is reabsorbed** from the colon → systemic ammonia rises. - **At acidic pH:** NH4+ (charged, water-soluble) is favored; it **cannot cross cell membranes and remains trapped in the colonic lumen** → ammonia is **excreted in stool instead of being reabsorbed.** - **Osmotic laxative effect:** Lactulose pulls fluid into the colon, **increases stool frequency and reduces transit time,** allowing less time for ammonia reabsorption. - **Bacterial reduction:** Lactulose fermentation **shifts the colonic flora from ammonia-producing bacteria** (proteolytic) **toward lactate/acetate-producing bacteria,** reducing ammonia generation itself. **Dosing:** - **Initial:** **30-45 mL (or 20-30 g) of lactulose syrup orally 2-4 times daily.** - **Titration:** Increase dose **every 2-4 days if needed,** aiming for **2-3 SOFT STOOLS PER DAY.** The goal is **NOT diarrhea or loose stools per se;** rather, **2-3 soft, formed stools** indicate adequate ammonia clearance without dehydration. - **If patient cannot swallow:** Lactulose can be given as a **retention enema** (300 mL lactulose mixed with 700 mL water or saline; retain 30-60 minutes), effective for acute episodes. - **Maintenance:** Once HE resolves, continue lactulose at the dose that produces 2-3 soft stools daily for **chronic suppression and prevention of recurrence.** **Critical teaching points:** - **The goal is 2-3 SOFT stools, NOT diarrhea.** If the patient develops loose, watery stools, this indicates over-dosing → risk of **dehydration, electrolyte loss (hypokalemia, hyponatremia), acute kidney injury, and paradoxical worsening of encephalopathy.** Reduce the dose immediately. - **Bloating and abdominal discomfort** are common initially (from bacterial fermentation producing gas); these usually improve over days. - **Compliance is often poor** because patients dislike the sweetness (dilute with juice), or gastrointestinal side effects discourage continuation. Nurse education and monitoring are essential. **Monitoring while on lactulose:** - Daily or q2-3 day bowel movements: color, consistency, frequency. Record in chart. - Ammonia level: Serial measurements to assess trend (though clinical improvement is the best indicator). - Electrolytes: K+, Na+, Cl- (watch for hypokalemia and hyponatremia from diarrhea/diuretic use). - Renal function: Creatinine, BUN (dehydration from over-dosing increases azotemia). - Neuro status: Orientation, asterixis, sleep-wake cycle each shift. - Weight: Monitor for dehydration (loss >1 kg/day). **3. RIFAXIMIN (Antibiotic for Ammonia-Producing Bacteria):** - **Dose:** 550 mg orally twice daily (or 200 mg three times daily in some regimens). - **Mechanism:** Non-absorbed antibiotic; reduces ammonia-producing colonic bacteria (gram-negative rods and proteolytic anaerobes). - **Indication:** Often **added to lactulose for acute HE or as a maintenance agent;** considered in patients who cannot tolerate lactulose or have recurrent HE despite adequate lactulose dosing. - **Advantage:** Non-absorbable, minimal systemic side effects; can be used long-term. - **NLE context:** Lactulose is first-line; rifaximin is a valuable adjunct but not a replacement. **4. OTHER SUPPORTIVE MEASURES:** - **Restrict protein transiently during acute episodes:** Modern practice avoids prolonged severe protein restriction (causes malnutrition and muscle wasting); **use 1-1.5 g/kg for a few days during acute HE, then gradually advance** as mental status improves. **Plant-based proteins (beans, nuts) are better tolerated** than meat (higher branched-chain amino acid to aromatic amino acid ratio favors ammonia uptake into muscle). - **Adequate carbohydrate and fat:** Provide non-protein calories to prevent catabolism. - **Zinc supplementation:** Zinc is a cofactor for urea-cycle enzymes; **deficiency is common in cirrhosis** (aldosterone-induced urinary zinc loss). Supplementation (25-50 mg/day zinc gluconate) may improve ammonia metabolism. Not first-line but supportive. - **Branched-chain amino acid (BCAA) supplements:** Leucine, isoleucine, valine compete with aromatic amino acids (tyrosine, tryptophan) for brain uptake; BCAAs may reduce false neurotransmitter production. Specialized supplements for liver disease contain higher BCAA ratios; used in some centers as an adjunct. - **Vitamin supplementation:** Thiamine, folate, vitamin A, vitamin K (especially if alcohol-related cirrhosis or malabsorption). - **Adequate hydration:** Maintain euvolemia; IVs if unable to drink (but avoid free water—use isotonic/hypertonic fluids if hyponatremia). - **Avoidance of sedatives and opioids:** These worsen HE; use non-pharmacologic pain relief if possible, or use lowest effective doses of short-acting agents (acetaminophen for pain, lorazepam q4-6h PRN for agitation, only if essential). **5. ACUTE SEVERE HE (Grade 3-4) IN AN ICU SETTING:** - **Airway protection:** Intubation and mechanical ventilation if unable to protect airway (GCS ≤8). - **ICP monitoring:** Cerebral edema is a risk; head of bed 30 degrees, osmotic agents (mannitol, hypertonic saline), sedation/paralysis if intubated. - **Octreotide:** If variceal bleeding is contributing, octreotide infusion reduces splanchnic/portal flow (see Esophageal Varices section). - **Vasopressors and pressors:** If hypotensive (hepatorenal syndrome risk). - **TIPS or liver transplant:** Urgent evaluation if HE does not improve with medical management or if recurrent; transplant is the only definitive cure. **NURSING DIAGNOSES IN HE (NANDA):** - **Acute Confusion** related to elevated ammonia and hepatic toxins → Monitor orientation, asterixis, neuro checks q2-4h; safety precautions (bed rails, fall prevention); reorient frequently. - **Risk for Injury** related to confusion and altered mobility → Fall precautions, supervised ambulation, clear environment of hazards, call bell within reach. - **Constipation** (or paradoxically, diarrhea if lactulose over-dosed) related to portal hypertension and bowel motility → Monitor bowel function; lactulose titration; adequate hydration and fiber. - **Imbalanced Nutrition** related to altered taste, nausea, and protein restriction → Small frequent meals, nutritional support, involve dietitian, gradual protein advancement as HE resolves. - **Ineffective Self-Health Management** related to complexity of lactulose dosing and triggers → Patient/family education, written instructions, phone follow-up, involvement of case management. **PATIENT & FAMILY EDUCATION ON HE:** 1. **Recognize early signs:** Confusion, difficulty concentrating, mood changes, forgetfulness, sleep disturbance, new tremor. Report these immediately. 2. **Avoid HE precipitants:** - **Protein restriction:** Avoid excessive meat; encourage plant-based proteins when stable. - **Prevent constipation:** Eat adequate fiber (fruits, vegetables), drink 8-10 glasses of water/day, take lactulose as prescribed. - **Avoid NSAIDs:** Increase infection risk and ammonia production; use acetaminophen if needed, with caution (no >2-3 g/day in liver disease). - **Avoid sedatives and alcohol:** Absolutely no alcohol; discuss any sedative use with the hepatologist. 3. **Lactulose use:** Take as prescribed to achieve 2-3 soft stools/day; if diarrhea develops, reduce dose. Report lack of bowel movements or excessive loose stools. 4. **Infection prevention:** Report fever, dysuria, productive cough, or abdominal pain immediately (infection is a common HE trigger). 5. **Medication adherence:** Take all prescribed medications (diuretics, prophylactic antibiotics, zinc, vitamins). 6. **Follow-up:** Regular hepatology clinic visits; ammonia levels monitored; liver function followed.

**Esophageal varices** are dilated, tortuous veins in the submucosa of the esophagus (and sometimes gastric fundus) that develop as a result of **portal hypertension**, a hallmark of advanced cirrhosis. Rupture of varices causes **massive hematemesis and melena—one of the most life-threatening emergencies in cirrhosis**, with mortality rates of 20-30% per bleeding episode if untreated. **PATHOPHYSIOLOGY:** Portal hypertension (portal vein pressure >12 mmHg; normal is 5-10 mmHg) develops when cirrhotic fibrosis increases resistance to blood flow through the liver. In response, the portal vascular system develops **portosystemic collaterals** (shunts) to **decompress the high-pressure portal system.** The esophagus and gastric cardia are common sites of collateral formation because: 1. The **left gastric (coronary) vein** drains into the portal vein. 2. Increased portal pressure forces blood to flow backward through the left gastric vein into the **azygos venous system** (superior vena cava), bypassing the liver. 3. The esophageal submucosa is thin and distensible, so veins dilate progressively, forming **varices** (varicose veins). 4. Increased blood flow through these thin-walled, high-pressure varices makes them prone to **rupture, especially if intra-esophageal pressure increases** (coughing, vomiting, eating rough food). Other portosystemic collaterals develop (rectal varices, anterior abdominal wall caput medusae, hemorrhoids), but **esophageal varices are the most common source of life-threatening hemorrhage** in cirrhosis. **CLINICAL PRESENTATION OF VARICEAL BLEEDING:** - **Sudden, massive hematemesis** (often bright red blood). - **Melena** (black, tarry stools) indicating upper GI bleeding. - **Signs of hypovolemic shock:** Tachycardia (>100 bpm), hypotension, decreased urine output, altered mental status. - **Abdominal exam:** May show ascites, hepatomegaly, splenomegaly (portal hypertension stigmata). - **History:** Often, a cirrhotic patient with known varices or recent NSAIDs, aspirin use, or a minor trauma (vomiting from any cause) that precipitated the bleed. **RISK STRATIFICATION (Predictors of Variceal Bleeding):** - **Variceal size:** Large varices (>5 mm) have a 5-year bleeding risk of ~60%; small varices, ~10%. - **Red signs on varices** (during endoscopy): Cherry red spots, red wale marks, hematocystic spots = high risk. - **Degree of liver dysfunction:** Child-Pugh Class C (severe) > Class B > Class A. - **Portal pressure gradient:** HVPG (hepatic venous pressure gradient) >12 mmHg carries higher bleeding risk. **ACUTE MANAGEMENT OF VARICEAL BLEED (Medical Emergency):** **Immediate (First Minutes—ABCs):** 1. **Airway & Oxygenation:** - **High aspiration risk:** Patient is vomiting blood; may have impaired airway reflexes if encephalopathy present. - **Position:** Left lateral decubitus (to protect airway from aspiration). - **Supplemental O2:** Ensure SpO2 >90%. - **Consider intubation:** Elective endotracheal intubation is often performed **BEFORE endoscopy** if GCS ≤8, ongoing hematemesis precluding visualization, or respiratory compromise—much safer than performing endoscopy on an unprotected airway with ongoing bleeding. - **Type of intubation:** Use a cuffed endotracheal tube to prevent aspiration (do NOT use a nasogastric tube for intubation; use oral route). 2. **Vascular Access & Fluids:** - **Two large-bore IVs (18-gauge or larger).** Some protocols use a central line (internal jugular vein), but peripheral access is usually faster in emergency; central lines can follow. - **Crystalloid resuscitation:** Start **normal saline or Ringer's lactate** rapidly; however, **avoid over-resuscitation**, as excessive fluid administration increases portal pressure and paradoxically worsens variceal bleeding. **Target MAP >65 mmHg and Hgb >7-8 g/dL** (not the usual "2 units of blood per unit of PRBC lost" rule—a more conservative transfusion goal is used in variceal bleeding because transfusion increases portal pressure). - **Blood products:** Have type & cross for PRBCs, FFP, and platelets ready. Give PRBCs if Hgb <7 g/dL or ongoing bleeding; FFP if PT/INR significantly prolonged (ratio 1 unit FFP per 5 kg body weight, or 10-15 mL/kg); platelets if count <50,000/μL during active bleeding. 3. **Vasoactive Drugs (Reduce Splanchnic/Portal Blood Flow):** - **Octreotide** (somatostatin analog) **IV bolus 50 mcg followed by 50 mcg/hour infusion.** Works within minutes by reducing splanchnic arteriolar vasodilation and portal blood flow. Continue infusion for 5 days (decreases rebleeding risk during that window). **This is the first-line vasoactive agent in the U.S. and many developed countries.** - **Vasopressin & terlipressin** (alternatives): Vasopressin 0.4 units IV bolus, then 0.4 units/min infusion (less commonly used now due to systemic side effects—coronary vasoconstriction, arrhythmias—but effective). Terlipressin (selective V1-receptor agonist) has fewer systemic side effects and better bleeding control than vasopressin; used as first-line in Europe/Asia. - **Propranolol or nadolol** (non-selective beta-blockers) are **NOT first-line for acute bleeding** (too slow) but are given **AFTER bleeding is controlled** to prevent rebleeding. 4. **Endoscopy (URGENT—within 12 hours, ideally within 2 hours):** - **Gold standard for diagnosis and treatment.** - **Endoscopic band ligation (EBL):** Preferred endoscopic technique. A rubber band (ligature) is deployed over the varix via an endoscopic banding device; the band strangles the varix, which necrotizes and sloughs in 1-2 weeks. **Success rate ~80-90%;** low rebleeding and mortality. - **Endoscopic sclerotherapy:** Injection of sclerosing agent (e.g., cyanoacrylate/tissue adhesive, sodium tetradecyl sulfate) directly into or adjacent to the varix to thrombose it. Effective but **higher rebleeding rate than EBL and more esophageal ulceration complications.** Increasingly replaced by EBL but still used in some centers, especially for gastric varices (cyanoacrylate preferred for gastric varices). - **Repeat endoscopy:** EBL is typically repeated at 1-4 week intervals until variceal eradication (complete obliteration of varices). 5. **Antibiotics (Prophylaxis for Bacterial Infection/SBP):** - **Bacterial translocation and SBP risk increased in variceal bleeding.** - **First-line:** Ceftriaxone 1 g IV q12h for 7 days, OR norfloxacin 400 mg orally BID for 7 days (if mild, can use PO). - **Benefit:** Reduces bacterial infection, rebleeding, and mortality by ~20%. 6. **Correction of Coagulopathy (if time permits before endoscopy):** - **Vitamin K:** 10 mg IV slowly (works over 12-24 hours; too slow for acute bleeding but give anyway). - **Fresh frozen plasma (FFP):** 10-15 mL/kg if PT/INR severely prolonged (>1.5); goal INR <2.0 before invasive procedures. - **Platelets:** Transfuse if <50,000/μL and active bleeding. - **Recombinant Factor VIIa:** Experimental; improves coagulopathy but no clear mortality benefit in randomized trials; rarely used acutely. 7. **Monitoring & Reassessment:** - **Vital signs q15 min initially,** then q30-60 min as stable. - **Hemoglobin/hematocrit:** Serial labs (initially q2-4h, then q6-8h as stable); watch for ongoing bleeding (persistent anemia despite transfusion). - **Coagulation profile (PT/INR, aPTT),** platelets, creatinine, glucose. - **Urine output:** Goal >0.5 mL/kg/hour; catheterize if needed. - **Mental status:** Watch for encephalopathy (worsens with blood [protein] and hypotension). **RESCUE THERAPIES FOR REFRACTORY VARICEAL BLEEDING (Uncontrolled after 2 Endoscopic Attempts):** 1. **Balloon Tamponade (Sengstaken-Blakemore or Minnesota Tube):** - **Mechanism:** Two balloons (gastric and esophageal) compress varices mechanically. - **Indications:** Refractory bleeding (fails 2 endoscopic attempts); temporizing measure while awaiting transplant or TIPS. - **Procedure:** Tube is passed nasally or orally (usually orally in emergency); gastric balloon inflated with 250 mL air, esophageal balloon with up to 40 mmHg pressure (gauged manometer). Continuous monitoring. - **Complications:** Tube migration, esophageal rupture (if over-pressurized), aspiration (if not intubated), ischemic necrosis of esophageal mucosa. - **Critical nursing point:** **KEEP SCISSORS AT THE BEDSIDE TO IMMEDIATELY DEFLATE OR CUT THE TUBE IF THE PATIENT HAS RESPIRATORY DISTRESS OR SIGNS OF AIRWAY OBSTRUCTION.** This is a life-saving intervention in case of tube malposition or migration. - **Duration:** Usually 12-48 hours; remove within 48 hours due to mucosal necrosis risk. Re-bleed rate is ~50% after removal. 2. **TIPS (Transjugular Intrahepatic Portosystemic Shunt):** - **Procedure:** Radiologist creates a conduit within the liver between the portal and hepatic vein via a catheter placed through the internal jugular vein. Stent deployment maintains the shunt, decompressing the portal system. - **Indications:** Refractory variceal bleeding (fails endoscopy ± balloon tamponade), refractory ascites, hepatic budd-chiari syndrome. - **Success:** ~90% hemostasis rate; effective for preventing rebleeding. - **Complications:** Shunt thrombosis (requires revision), encephalopathy (worsens by shunting ammonia-rich blood past the liver), liver failure progression. - **Outcome:** Improves short-term survival in refractory bleeding but does NOT replace transplant as definitive therapy. 3. **Liver Transplantation:** - **Definitive treatment** for variceal bleeding refractory to medical and endoscopic therapy. - **Candidate selection:** Urgent evaluation if refractory bleed; MELD (Model for End-Stage Liver Disease) score determines priority on transplant list. **PREVENTION OF FIRST & RECURRENT VARICEAL BLEED:** **Primary Prevention (No prior bleed):** - **Screening:** Endoscopy in all cirrhotics to identify varices; repeat q1-3 years if no varices, every 1-2 years if small varices without red signs, q6 months or sooner if large varices or red signs. - **Pharmacotherapy:** **Non-selective beta-blockers (propranolol or nadolol) reduce portal pressure and are first-line.** - **Propranolol:** 20 mg PO BID, increase by 20 mg each week to target **25% reduction in heart rate** (e.g., HR from 80 to 60 bpm) or goal HR 55-60 bpm. Maximum dose ~320 mg/day divided into 2-3 doses. - **Nadolol:** 40 mg PO daily, titrate similarly; longer half-life, once-daily dosing preferred by some. - **Carvedilol:** Alternative non-selective beta-blocker; 6.25 mg daily; blocks beta and alpha receptors (additional vasodilation). Increasingly used. - **Efficacy:** Reduces bleeding risk by ~45% and mortality by ~10% (absolute benefit modest but clinically significant). - **Adverse effects:** Fatigue, sexual dysfunction, bronchospasm (contraindication in asthma/COPD), and worsening of decompensation (hepatorenal syndrome) in a small subset—monitored closely. - **Endoscopic band ligation:** Considered in some centers as primary prophylaxis in patients with large varices or those who cannot tolerate beta-blockers. **Secondary Prevention (After a bleed):** - **Beta-blockers:** Continued indefinitely; target same heart rate reduction. - **Endoscopic band ligation:** **Standard; repeated at intervals until variceal eradication.** First session occurs during acute bleeding hospitalization or within 5-7 days. Subsequent sessions every 1-4 weeks until varices obliterated. Then surveillance endoscopy q6-12 months. - **Combination therapy:** Beta-blockers + EBL superior to either alone; standard of care post-bleed. - **Nitrates (isosorbide mononitrate):** May be added to beta-blockers for additional portal pressure reduction in some settings; not first-line. - **Rebleeding rate:** With EBL + beta-blockers, ~20% over 2 years (significantly better than historical sclerotherapy or medical therapy alone). **NURSING DIAGNOSIS & CARE IN VARICEAL BLEEDING:** **Hemorrhage & Shock (Immediate Life Threat):** - **Hypovolemic Shock** related to massive GI hemorrhage → Rapid vascular access, fluid/blood resuscitation, continuous monitoring of vital signs, urine output, mental status. - **Risk for Aspiration** related to hematemesis and altered airway reflexes → Position left lateral, NPO, prepare for intubation, suction available. - **Ineffective Tissue Perfusion** related to hypovolemia → Monitor MAP, lactate, base deficit; escalate to vasopressors if needed. **Nursing Actions:** - **Two large-bore IVs;** avoid central line if possible (delays peripheral access). - **Continuous monitoring:** Telemetry, pulse oximetry, BP q15-30 min; Foley catheter (urine output goal >0.5 mL/kg/hour). - **Serial labs:** Hgb/Hct (watch for ongoing bleeding—failure to rise after transfusion indicates continued bleeding), coagulation studies, creatinine, glucose, electrolytes. - **Supportive care:** Position semi-Fowler's (if stable) or left lateral (high aspiration risk); NPO; ice chips if patient requests (avoid ice water—controversial; some protocols avoid); mouth care. - **Medication administration:** Octreotide IV infusion (50 mcg bolus, then 50 mcg/hour), antibiotics (ceftriaxone 1 g q12h), vitamin K 10 mg IV, FFP/PRBCs as ordered. - **Prepare for endoscopy:** Ensure consent, NPO status, keep patient calm, explain procedure (patient may be very anxious). - **Post-endoscopy:** Continue octreotide x5 days, beta-blockers (propranolol) once bleeding controlled, PPI (famotidine 20 mg IV q12h, or omeprazole 40 mg daily) to reduce rebleeding risk, repeat endoscopy per protocol for EBL completion. - **Balloon tamponade (if needed):** Ensure tube secured; mark nostril/mouth at entry point; monitor for tube migration (abdominal X-ray confirmation); watch for respiratory distress; **SCISSORS AT BEDSIDE**; deflate esophageal balloon q12h for brief period to reduce ischemia risk; plan removal within 48 hours. **Post-Acute Bleed Education:** - **Adherence to beta-blockers:** Critical for preventing rebleeding; explain why (reduces portal pressure). - **Comply with endoscopy schedule:** Attend all follow-up EBL sessions until varices eradicated; then surveillance q6-12 months. - **Avoid NSAIDs, aspirin, anticoagulants** (unless absolutely necessary, e.g., mechanical heart valve—coordinate with hepatologist). - **Avoid hard/rough foods:** Soft diet reduces mucosal trauma and rebleeding risk. - **Report hematemesis, melena, coffee-ground emesis immediately** — seek emergency care. - **Avoid alcohol absolutely,** as it impairs coagulation, causes gastritis, and worsens liver disease. - **Medication list review:** Make sure patient/family understand beta-blocker names, doses, and adverse effects.

**Cholelithiasis** refers to the **presence of gallstones** (calculi) within the gallbladder, which may be **asymptomatic (silent stones)** or lead to **biliary colic** (pain). **Cholecystitis** is **inflammation of the gallbladder wall,** most often precipitated by a stone impacting the **cystic duct** (acute calculous cholecystitis), less commonly due to bile stasis without stones (acalculous cholecystitis). Both are common, painful, and a major reason for acute abdominal emergencies in the Philippines and globally. **EPIDEMIOLOGY & RISK FACTORS:** **The "5 F's" mnemonic for cholelithiasis risk (classic NLE board question):** 1. **Female** — Women are 2-3× more likely to develop stones (estrogen increases cholesterol saturation of bile). 2. **Fat (Obesity)** — BMI >30 associated with higher stone incidence; rapid weight loss also increases risk (cholesterol concentration). 3. **Forty** — Incidence peaks in the 4th-6th decades of life. 4. **Fertile (Multiparity)** — Pregnancy and oral contraceptive use increase lithogenicity of bile. 5. **Fair (Caucasian ethnicity)** — Though stones occur in all ethnicities; some populations (Native Americans, Scandinavians) have higher incidence. **Other risk factors:** - **Diabetes mellitus** (bile stasis, altered cholesterol metabolism). - **Cirrhosis and biliary obstruction** (increased bile stasis). - **Hemolytic anemia** (bilirubin-rich pigment stones). - **Prolonged fasting or TPN** (bile stasis, cholecystokinin-CCK suppression). - **Ileal disease/resection** (impaired bile acid reabsorption, loss of feedback inhibition of cholesterol secretion). - **Medications:** Estrogens, octreotide, ceftriaxone (all promote stone formation by various mechanisms). **TYPES OF GALLSTONES:** - **Cholesterol stones** (~80-90%): Form when bile becomes supersaturated with cholesterol; risk factors as above. - **Pigment stones (Bilirubin-rich)** (~10-20%): - **Black pigment stones:** Hemolysis, cirrhosis, chronic hemolytic anemia (unconjugated bilirubin). - **Brown pigment stones:** Biliary tract infection, oriental cholangiohepatitis (associated with parasites in SE Asia, including Philippines). - **Mixed stones:** Cholesterol core with pigment layers. **ASYMPTOMATIC (SILENT) CHOLELITHIASIS:** - Stones are present but patient is asymptomatic. - Discovered incidentally on ultrasound for other reasons. - **Management:** Generally **NO prophylactic cholecystectomy** (risk of surgery exceeds risk of future symptoms; only ~1% per year develop symptoms). **Exception:** Cholecystectomy is recommended in: - **Cirrhosis with portal hypertension** (high surgical risk; prevent emergency surgery later). - **Solitary kidney or renal transplant** (protect remaining kidney function; avoid sepsis/shock from acute cholecystitis). - **Sickle cell disease** (hemolysis; risk of vasoocclusive crisis from cholecystitis). - **Immunosuppression** (risk of severe/gangrenous cholecystitis). - **Calcified ("porcelain") gallbladder** (~37% malignancy risk; prophylactic cholecystectomy recommended). **ACUTE CHOLECYSTITIS (CALCULOUS):** **Pathophysiology:** A gallstone impacts the cystic duct → bile becomes static behind the obstruction → increased cystic duct pressure, secondary bacterial infection, and mucosal inflammation/edema. If unrelieved, the inflammatory process progresses to **gangrenous cholecystitis** (transmural necrosis) and **perforation** (bile peritonitis, septic shock, high mortality). **Clinical Manifestations:** 1. **Pain:** (Classic NLE feature) - **Right-upper-quadrant (RUQ) pain**, often **colicky** in onset (sharp, crampy), but **constant in acute cholecystitis** (unlike biliary colic which is intermittent). - **Radiation:** Often radiates to the **right shoulder or right scapula** (from visceral innervation; phrenic nerve). - **Onset:** Often **postprandial, especially after fatty meals** (fatty foods stimulate CCK release → gallbladder contraction → pain if stone is obstructing). - **Duration:** Pain may last hours (biliary colic is 30 minutes to several hours; acute cholecystitis is >6 hours). - **Associated symptoms:** Nausea, vomiting, anorexia. 2. **Physical Examination:** - **Murphy's sign (highly suggestive of acute cholecystitis):** Examiner places hand under the RUQ just below the costal margin, below where the gallbladder is located. Patient is asked to take a deep breath. In acute cholecystitis, as the inflamed gallbladder fundus descends during inspiration, it contacts the examiner's hand → **inspiratory arrest** (sudden stop to the patient's inspiration due to pain). This is **positive Murphy's sign** and is ~85% sensitive for acute cholecystitis. - **RUQ tenderness & guarding:** May progress to peritoneal signs (rebound, rigidity) if perforation. - **Palpable mass:** Rarely, inflamed gallbladder or omentum forms a mass. - **Fever:** Usually mild (38-38.5°C); high fever suggests complications (gangrenous cholecystitis, perforation, sepsis). 3. **Laboratory Findings:** - **Elevated WBC** (typically 10,000-15,000/μL; >15,000 or left shift suggests complicated cholecystitis). - **Elevated alkaline phosphatase (ALP)** and **gamma-glutamyl transferase (GGT)** (from biliary obstruction/cholestasis). - **Mild elevation of ALT/AST** (hepatocellular inflammation from blocked bile flow). - **Elevated bilirubin (total and conjugated)** if common bile duct obstruction (choledocholithiasis) — stones in the CBD cause jaundice, dark urine, pale stools, and possibly **acute pancreatitis** (stone transiently blocks the ampulla of Vater). - **Normal amylase/lipase** unless stones migrate to CBD → pancreatitis (in which case amylase/lipase markedly elevated). 4. **Imaging (Gold Standard: Abdominal Ultrasound):** - **Ultrasound (US) is the best initial test** for suspected cholecystitis: - **Gallstones visible** (echogenic foci with acoustic shadow if large enough). - **Thickened gallbladder wall** (>3 mm suggests inflammation). - **Positive sonographic Murphy's sign:** Tenderness directly over the gallbladder on US probe pressure (more objective than physical exam). - **Dilated CBD** if obstruction. - **Pericholecystic fluid** if severe inflammation/beginning perforation. - **Sensitivity & Specificity:** >95% for detecting gallstones; ~80-90% for acute cholecystitis. - **HIDA scan (hepato-iminodiacetic acid):** Functional test; shows bile flow. Nonvisualization of gallbladder after 4 hours suggests cystic duct obstruction (acute cholecystitis). Used if US inconclusive or acalculous cholecystitis suspected. - **CT:** For complications (perforation, abscess, pancreatitis). Better for evaluating acalculous disease. **ACUTE MANAGEMENT OF CHOLECYSTITIS:** 1. **NPO** (nothing by mouth): Rests the biliary system; avoids triggering further contractions. 2. **IV Fluids & Electrolytes:** Dehydration is common; replace deficits (calculate from daily maintenance + losses). 3. **Pain Management:** - **Analgesia:** Morphine or hydromorphone IV PRN q3-4h. (Note: classic teaching warned against morphine because it may cause sphincter of Oddi spasm; modern practice recognizes this is clinically insignificant compared to pain relief urgency.) - **Avoid NSAIDs initially** (may increase pancreatic inflammation if pancreatitis develops; wait until diagnosis clarified). 4. **Antibiotics (for acute cholecystitis with systemic infection signs):** - **Empirical coverage** of gram-negatives (E. coli) and gram-positives (enteric flora often implicated). - **Regimens:** Ceftriaxone 1-2 g IV q12h + metronidazole 500 mg IV q6-8h, OR cefoxitin 2 g IV q6h (broader coverage) × 7-10 days. 5. **Definitive Treatment: Laparoscopic Cholecystectomy (Gold Standard)** - **Timing:** Elective within 1-2 weeks in uncomplicated acute cholecystitis (after inflammation resolves slightly); emergency if perforation, gangrenous disease, or toxic presentation. - **Approach:** **Laparoscopic** is preferred over open (less morbidity, faster recovery, shorter hospital stay, better cosmetics). Success rate ~85-90%; if difficult anatomy or complications, conversion to open is done. - **Operative findings:** Stone(s) in gallbladder, inflamed wall, sometimes omentum adherent to gallbladder or CBD stones (recognized during surgery or ERCP). - **Post-operative course:** - Discharge often 24-48 hours post-op (outpatient or next-day surgery). - Activity restriction for 4-6 weeks (avoid heavy lifting, strenuous activity). - Pain control with acetaminophen or oral NSAIDs (low risk post-op). - Gradual diet advancement: clear liquids → regular diet, though **low-fat diet for 4-6 weeks** (some patients develop **post-cholecystectomy diarrhea** from bile flowing continuously into intestine; low-fat diet reduces this, and most resolve in weeks to months). **Complications of Cholecystitis:** - **Biliary pancreatitis:** Stone transits ampulla of Vater → acute pancreatitis (see Section 6). Risk resolves once stone passes or is removed. - **Cholangitis:** Stone obstructs CBD → bile stasis, bacterial overgrowth, ascending infection → fever, jaundice, RUQ pain (Charcot's triad: fever + jaundice + RUQ pain; + altered mental status + hypotension = Reynolds' pentad in septic cholangitis). Managed with antibiotics + ERCP for stone extraction. - **Gangrenous cholecystitis & perforation:** Necrosis from inflammation; risk of bile peritonitis, sepsis, shock. Emergency cholecystectomy needed. Mortality high if delayed. - **Fistula (cholecystoenteric):** Chronic stone erodes through gallbladder wall into adjacent bowel (usually duodenum); rare; stone may lodge distally causing "gallstone ileus" (mechanical small bowel obstruction). Risk in elderly. **NURSING DIAGNOSES & CARE (ACUTE CHOLECYSTITIS):** **Pain (Acute):** - **Acute Pain** related to gallbladder inflammation and distension → IV analgesia (morphine or hydromorphone q3-4h PRN), positioning (semi-Fowler's, right side lying), relaxation techniques, heat pads (if available; some institutions avoid due to perforation risk), reassurance. **Fluid & Nutrition:** - **Imbalanced Nutrition: Less Than Body Requirements** related to NPO status and nausea → IV fluids, antiemetics (ondansetron 4-8 mg IV q6-8h PRN), NPO until pain/vomiting resolves, then clear liquids → full diet as tolerated post-operatively. - **Fluid Volume Deficit** related to vomiting and NPO → Maintain IV access, monitor I&O, replace electrolytes, monitor weight. **Pre-operative Preparation:** - Pre-op teaching: explain laparoscopic procedure (small incisions, faster recovery), NPO after midnight before surgery, expectation of post-op pain (briefly), activity restrictions, low-fat diet post-op. - Labs: CBC, CMP, coagulation studies, blood type & screen. - Consent: Explain risks (conversion to open, bile duct injury, bleeding). **Post-operative Nursing Care (First 24-48 hours):** - **Pain management:** IV/PO analgesia; assess pain q2-4h initially. - **Vital signs & monitoring:** Continuous pulse oximetry initially; monitor BP, HR, RR, temp q4h; report fever >38.5°C (possible infection). - **Incision care:** Small bandages over 4 small trocal incisions; assess for bleeding, drainage, signs of infection (redness, swelling, pus). - **Activity:** Encourage deep breathing and coughing (prevent post-op atelectasis); early ambulation (within hours if stable); gradually increase activity. - **Diet:** NPO until bowel function returns (flatus, bowel movement); start clear liquids, advance to regular diet as tolerated; low-fat diet for 4-6 weeks. - **I&O:** Monitor urine output; encourage oral fluids as tolerated. - **Complications watch:** Fever, increasing pain, distension, bile-stained drainage (bile duct injury), signs of bleeding. **Discharge Instructions:** - Incision care: keep dry, report redness/swelling/pus. - Pain: acetaminophen or ibuprofen PRN; avoid narcotic analgesics after 1-2 weeks (risk of dependence). - Diet: low-fat for 4-6 weeks; gradual reintroduction of fats (if diarrhea develops, further restrict fat). - Activity: avoid heavy lifting, strenuous exercise for 4-6 weeks; light activities okay after 1-2 weeks. - Return to work: Most patients return in 1-2 weeks (desk job) to 4-6 weeks (physical labor). - Follow-up: See surgeon at 2 weeks post-op (wound check, progress assessment). - When to call: Fever >38.5°C, increased pain, persistent vomiting, bile-stained drainage, signs of infection. **ACALCULOUS CHOLECYSTITIS (IMPORTANT FOR NCM & CRITICAL CARE):** **Definition:** Acute gallbladder inflammation WITHOUT demonstrable stones. Accounts for ~5-10% of acute cholecystitis but carries **higher morbidity/mortality** (more often complicated by perforation, gangrene). **Risk factors:** - **Critical illness:** Sepsis, major trauma, extensive surgery, burns. - **Bile stasis:** Prolonged NPO, TPN without cholecystokinin stimulation. - **Ischemia:** Hypotension, cardiac failure, atherosclerosis of cystic artery. - **Infection:** CMV (immunocompromised), Candida. - **Medications:** Octreotide, chemotherapy. **Diagnosis & Management:** - **Ultrasound:** No stones, but **thickened gallbladder wall, pericholecystic fluid, positive sonographic Murphy's sign.** - **HIDA scan:** Non-visualization (cystic duct obstruction from edema/debris, not stone). - **Management:** Similar to calculous—IV fluids, antibiotics, NPO, analgesia. **Cholecystostomy or percutaneous drainage** if very ill/unfit for surgery (allows decompression, reduces ischemia risk). **Cholecystectomy** once patient stabilizes (if necessary; some resolve with supportive care alone). - **Prognosis:** Guarded; mortality ~5-10% even with treatment (vs. <1% for uncomplicated calculous cholecystitis).